This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Scandion Oncology Toekomstige groei

-43.4%

Groei van de winst

-43.4%

Groei van de winst per aandeel

Biotechs winstgroei	45.6%
Inkomstengroei	81.1%
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	Low
Laatst bijgewerkt	n/a

Geen updates

Geen updates

Winst- en omzetgroeiprognoses

OM:SCOL BTA - Toekomstschattingen van analisten en financiële gegevens uit het verleden (DKK Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2023	1	-109	N/A	N/A	1
12/31/2022	1	-55	N/A	N/A	1
3/31/2022	N/A	-56	-57	-56	N/A
12/31/2021	N/A	-52	-50	-50	N/A
9/30/2021	N/A	-43	-48	-48	N/A
6/30/2021	N/A	-31	-34	-34	N/A
3/31/2021	N/A	-22	-24	-24	N/A
12/31/2020	N/A	-17	-17	-17	N/A
9/30/2020	N/A	-11	-8	-8	N/A
6/30/2020	N/A	-14	-14	-14	N/A
3/31/2020	N/A	-14	-12	-12	N/A
12/31/2019	N/A	-12	-10	-10	N/A
9/30/2019	N/A	-17	-21	-21	N/A
6/30/2019	N/A	-12	-16	-16	N/A
3/31/2019	N/A	-10	-15	-15	N/A
12/31/2018	N/A	-8	-13	-13	N/A
9/30/2018	N/A	-4	-3	-3	N/A

Verdiensten versus spaarpercentage: SCOL BTA is forecast to remain unprofitable over the next 3 years.

Winst versus markt: SCOL BTA is forecast to remain unprofitable over the next 3 years.

Hoge groeiwinsten: SCOL BTA is forecast to remain unprofitable over the next 3 years.

Omzet versus markt: SCOL BTA's revenue (81.1% per year) is forecast to grow faster than the Swedish market (9.3% per year).

Hoge groei-inkomsten: SCOL BTA's revenue (81.1% per year) is forecast to grow faster than 20% per year.

Toekomstige ROE: Insufficient data to determine if SCOL BTA's Return on Equity is forecast to be high in 3 years time